Morgan Stanley Maintains Overweight on Revolution Medicines, Lowers Price Target to $247
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.
Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.